Evaluation of the US Oncology Network’s Recommended Guidelines for Therapeutic Substitution with Darbepoetin alfa 200 µg Every 2 Weeks in Both Naïve Patients and Patients Switched from Epoetin alfa

This publication has 15 references indexed in Scilit:

• A multicenter retrospective cohort study of practice patterns and clinical outcomes of the use of darbepoetin alfa and epoetin alfa for chemotherapy-induced anemia
  Clinical Therapeutics, 2003
• The impact of frequent injections for hematopoietic growth factor support on patients receiving chemotherapy: an observational study
  BMC Nursing, 2003
• Behavioral Adjustment of Children and Adolescents With Cancer: Teacher, Parent, and Self-Report
  Oncology Nursing Forum, 2003
• PCN2: DARBEPOETIN ALFA 200 MCG EVERY 2 WEEKS (Q2W) AND EPOETIN ALFA 40,000 UNITS EVERY WEEK (QW) IN CHEMOTHERAPY-INDUCED ANEMIA PATIENTS RESULT IN SIMILAR INITIAL HEMOGLOBIN OUTCOMES
  Value in Health, 2003
• Control of cancer-related anemia with erythropoietic agents:a review of evidence for improved quality of life and clinical outcomes
  Annals of Oncology, 2003
• A randomized, active-control, pilot trial of front-loaded dosing regimens of darbepoetin-alfa for the treatment of patients with anemia during chemotherapy for malignant disease
  Cancer, 2003
• Randomized, dose‐finding study of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies
  British Journal of Haematology, 2002
• Double-Blind, Placebo-Controlled, Randomized Phase III Trial of Darbepoetin Alfa in Lung Cancer Patients Receiving Chemotherapy
  JNCI Journal of the National Cancer Institute, 2002
• Darbepoetin alfa given every 1 or 2 weeks alleviates anaemia associated with cancer chemotherapy
  British Journal of Cancer, 2002
• Decreased Erythropoietin Response in Patients with the Anemia of Cancer
  New England Journal of Medicine, 1990